OXAYDO is an immediate-release oral formulation of oxycodone HCl indicated for the Important Safety Information; Full Prescribing Information. OXAYDO.
The most common adverse reactions are nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia and somnolence. Serious adverse reactions that may be associated with OXAYDO include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock.
Mixed agonist/antagonist analgesics: may reduce the analgesic effects and/or may precipitate withdrawal symptoms.
OXAYDO may be abused by crushing, chewing, snorting or injecting the product and these practices pose a significant risk to the abuser that could result in overdose and death.
By Amanda Conschafter, blog editor. Physicians who prescribe opioid analgesics for kids with severe pain will now have the benefit of FDA.
Physicians sometimes prescribe the medication for children with pain that cannot be tempered by other medications – for instance, to treat car accident injuries, or chronic or migraine headaches. But in the past physicians have prescribed the medication off-label, relying upon prescribing information designed for adult patients.
Though parents can help ward off some headaches by ensuring adequate sleep and fluid intake, the National Headache Foundation reports that five percent of kids face migraine headaches. These can be accompanied by nausea and vomiting and may require treatment with medication.
That information may be well timed. New data suggests that heading back to school corresponds to a spike in headaches among the estimated 10.3 million American children who suffer from them. The Nationwide Children’s Hospital recently reported that emergency room visits by children with headaches spiked 31 percent in the fall.
For families whose children need prescription pain medication for headaches or other conditions, the FDA reiterates the importance of safe storage and proper disposal. It has also requested additional data in the coming years on extended-release oxycodone’s use among pediatric patients and any related adverse events. ###
by Amanda Conschafter, blog editor.
Physicians who prescribe opioid analgesics for kids with severe pain will now have the benefit of FDA guidance on pediatric dosing and safety. The FDA recently approved an extended-release form of the prescription pain reliever oxycodone for children age 11 and older.
The FDA’s approval came after the medication’s manufacturer submitted safety and efficacy data from clinical trials conducted with children. Regulators stress that the decision is “not intended to expand or otherwise change” prescribing patterns, but to better inform the prescribing that already occurs.
Primlev is a prescription drug for controlling moderate to moderay severe pain. bines two powerful pain relievers, oxycodone and The full prescribing information contains warnings regarding the potential for misuse, abuse.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800- FDA-1088 1088). 2016 Akrimax Pharmaceuticals, LLC.
The following information is intended for physicians only. Please confirm that you are a United States physician. Otherwise you will be redirected to the main website.
Primlev is a prescription drug for controlling moderate to moderay severe pain. bines two powerful pain relievers, oxycodone and acetaminophen, in a unique formulation that balances efficacy while reducing your risk for side effects. Your doctor may prescribe Primlev to treat pain after surgery or other types of moderate to moderay sever pain.
Primlev is trademarked by Mikart, Inc. Marketed and Distributed by Akrimax Pharmaceuticals, LLC, Cranford, NJ, 07016 USA.
HEPATOTOXICITY: ACETAMINOPHEN HAS BEEN ASSOCIATED WITH CASES OF ACUTE LIVER FAILURE, AT TIMES RESULTING IN LIVER TRANSPLANT AND DEATH. MOST OF THE CASES OF LIVER INJURY ARE ASSOCIATED WITH THE USE OF ACETAMINOPHEN AT DOSES THAT EXCEED 4000 MILLIGRAMS PER DAY, AND OFTEN INVOLVE MORE THAN ONE ACETAMINOPHEN-CONTAINING PRODUCT.
Mylan manufactures OXYCODONE & ASPIRIN Tablets, USP (Percodan) in strengths of 4.8355 Link to Prescribing information including all WARNINGS.
Please select one of our websites from the list below.
What to know about our high quality generics.
The product database is intended as a general reference source only and is not a substitute for qualified medical care from a licensed physician.
* Registered Trademark of Endo Pharmaceuticals Inc.
Educational materials to help empower your customers.
Details about our brand name and generic medicines.
2015 Mylan N.V.
Resources that meet the specific needs of your institution.
Audiences Only. For U.S.
Search our generic and brand name U.S. pharmaceuticals.
Mylan also is proud to do business in these locations.
HIGHLIGHTS OF PRESCRIBING INFORMATION See full prescribing information for OXECTA (oxycodone HCl) is an opioid agonist indicated for the.